Algernon Pharmaceuticals (AGNPF) News Today → My top 100 stocks… (From DTI) (Ad) Free AGNPF Stock Alerts $0.09 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024globenewswire.com - April 24 at 7:47 AMAlgernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024globenewswire.com - April 11 at 7:00 AMDMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Designmsn.com - April 3 at 6:45 PMAlgernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Assetglobenewswire.com - April 1 at 7:00 AMAlgernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatmentfinance.yahoo.com - March 28 at 10:24 AMCanadian Investment Regulatory Organization Trading Halt - AGNfinance.yahoo.com - March 27 at 2:32 PMCanadian Investment Regulatory Organization Trade Resumption - AGNfinance.yahoo.com - March 27 at 2:32 PMAlgernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by Seyltxproactiveinvestors.com - March 27 at 12:22 PMAlgernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Positionglobenewswire.com - March 27 at 12:04 PMAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKDfinance.yahoo.com - January 31 at 10:38 AMAlgernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosisfinance.yahoo.com - January 11 at 8:35 AMAlgernon Pharmaceuticals Announces Increase to Private Placementfinance.yahoo.com - December 27 at 10:16 AMAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLDfinance.yahoo.com - November 30 at 10:36 AMSeyltx acquires Algernon's chronic cough research program for $2M and 20% stakemsn.com - November 22 at 12:00 PMAlgernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Positionfinance.yahoo.com - November 22 at 12:00 PMAlgernon Pharmaceuticals Inc. (AGN.CN)uk.finance.yahoo.com - November 12 at 7:11 PMAlgernon gets Japanese patent notice of allowance for treatment of NASH with Repirinastmsn.com - November 8 at 10:15 AMAlgernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinastfinance.yahoo.com - November 8 at 10:15 AMAlgernon Pharmaceuticals Inc Class A (AGN)investing.com - September 9 at 6:40 AMAlgernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASHfinance.yahoo.com - September 6 at 11:31 AMDMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Studybenzinga.com - August 8 at 12:29 PMAlgernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Studyfinance.yahoo.com - August 8 at 7:29 AMAlgernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreementfinance.yahoo.com - July 14 at 9:14 PMAlgernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Programfinance.yahoo.com - June 27 at 7:46 AMAlgernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conferencefinance.yahoo.com - June 6 at 9:16 AMAlgernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose studyfinance.yahoo.com - June 5 at 5:42 PMAlgernon Pharmaceuticals subsidiary completes DMT escalating dose studyproactiveinvestors.com - June 5 at 12:41 PMAlgernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studiesfinance.yahoo.com - June 5 at 7:41 AMAlgernon Pharmaceuticals receives Notice of Allowance from Japanese Patent Office for Repirinastproactiveinvestors.com - May 31 at 1:20 PMAlgernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKDfinance.yahoo.com - May 31 at 8:20 AMAlgernon Pharmaceuticals Announces Closing of Rights Offeringfinance.yahoo.com - May 5 at 7:24 PMIIROC Trading Halt - AGN.RTfinance.yahoo.com - April 27 at 4:13 PMAlgernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Timefinance.yahoo.com - April 20 at 9:09 AMAlgernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASHfinance.yahoo.com - April 18 at 2:33 PMAlgernon Pharma receives Notice of Allowance from US Patent and Trademark Office for Repirinastproactiveinvestors.com - April 17 at 10:40 AMAlgernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Applicationfinance.yahoo.com - April 17 at 10:40 AMAlgernon NeuroScience reports successful second cohort dosing in DMT clinical studyfinance.yahoo.com - April 5 at 5:36 PMIntravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatmentbenzinga.com - April 4 at 4:17 PMAlgernon Pharmaceuticals announces successful dosing of second cohort in Phase 1 DMT clinical studyproactiveinvestors.com - April 4 at 11:17 AMAlgernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Studyfinance.yahoo.com - April 4 at 11:17 AMAlgernon Pharma says wholly-owned subsidiary's Reg A+ offering gets US SEC qualificationproactiveinvestors.com - April 3 at 12:48 PMAlgernon Pharmaceuticals: Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10Mfinanznachrichten.de - April 3 at 7:47 AMAlgernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10Mfinance.yahoo.com - April 3 at 7:47 AMFormer NFL neurologist joins Algernon's program using DMT to treat traumatic brain injuryproactiveinvestors.com - March 2 at 2:24 PMAlgernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Boardfinance.yahoo.com - March 2 at 9:24 AMAlgernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Programmsn.com - March 1 at 11:23 PMAlgernon Pharmaceuticals Announces 4 for 1 Forward Share Splitfinance.yahoo.com - March 1 at 1:21 PMDeveloping Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Programbenzinga.com - February 21 at 1:50 PMAlgernon Pharmaceuticals says unit initiates traumatic brain injury research program with DMT; appoints global TBI expert as advisorproactiveinvestors.com - February 21 at 1:50 PMAlgernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisorfinance.yahoo.com - February 21 at 8:49 AM Get Algernon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter. Email Address A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. AGNPF Media Mentions By Week AGNPF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGNPF News Sentiment▼-0.500.33▲Average Medical News Sentiment AGNPF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGNPF Articles This Week▼20▲AGNPF Articles Average Week Get Algernon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Artelo Biosciences News Today Ascletis Pharma News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today BriaCell Therapeutics News Today Clinuvel Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AGNPF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Algernon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
